Jasper’s Development Pipeline
Product candidate
Mechanism of action
Indications
DISCOVERY
PRECLINICAL
IND
PHASE 1
PHASE 2
PHASE 3
MARKET
KP-104
Anti-C5 mAb + Factor H Bifunctional Biologic
IgAN, C3G, FSGS
PNH
New indication
Briquilimab
Anti-KIT
SCID conditioning
Mast-cell mediated diseases
KP-701
Anti-CD79B
Autoantibody-mediated disorders
Undisclosed
Long-acting complement-targeted biologics
Autoimmune inflammatory disorders
IgAN; IgA Nephropathy. C3G; Complement 3 Glomerulopathy. FSGS; Focal Segmental Glomerulosclerosis. PNH; Paroxysmal nocturnal hemoglobinuria. SCID; Severe Combined Immunodeficiency.
EXPANDED ACCESS
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Jasper does not currently provide access to our investigational therapies under Expanded Access.